Literature DB >> 10443704

Development of monoclonal antibodies against the human sodium iodide symporter: immunohistochemical characterization of this protein in thyroid cells.

M R Castro1, E R Bergert, T G Beito, B McIver, J R Goellner, J C Morris.   

Abstract

The thyroid sodium-iodide symporter (NIS) is responsible for iodide concentrating ability within thyroid follicular cells. We sought to develop monoclonal antibodies against human NIS (hNIS) for use as reagents in structure-function studies of the protein, as well as potential tools in the assessment of NIS expression in benign and malignant thyroid tissues. Synthetic peptides corresponding to the second ExMD and to the carboxy-terminal ExMD of hNIS were produced and utilized as antigens to develop monoclonal antibodies, which were tested by Western blotting using membranes prepared from COS-7 cells transiently transfected with a pcDNA3 plasmid containing the gene for the full-length hNIS, or a control vector. Western blotting showed a major band with molecular weight (MW) of approximately 97 kDa and several minor bands with MW of approximately 160 kDa, 68 kDa, 30 kDa, and 15 kDa, all specific for hNIS-transfected cells. Immunohistochemistry was performed in various types of thyroid tissues and nonthyroidal tissues, using the monoclonal antibodies. Strong immunostaining was observed in Graves' tissue, intermediate staining in papillary and follicular thyroid cancer, and no staining in Hürthle cell cancer or in nonthyroidal tissue. The staining was specific for the follicular epithelium in each of the tissues and was most intense in the basolateral portion of the cell membrane. Overall, our observations indicate that the monoclonal antibodies are specific for hNIS and will be invaluable reagents for investigating the role of NIS in thyroid disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443704     DOI: 10.1210/jcem.84.8.5871

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer.

Authors:  Roisin M Dwyer; James Ryan; Ronan J Havelin; John C Morris; Brian W Miller; Zhonglin Liu; Richard Flavin; Cathal O'Flatharta; Mark J Foley; Harrison H Barrett; J Mary Murphy; Frank P Barry; Timothy O'Brien; Michael J Kerin
Journal:  Stem Cells       Date:  2011-07       Impact factor: 6.277

Review 2.  From Catheter to Kidney Stone: The Uropathogenic Lifestyle of Proteus mirabilis.

Authors:  Allison N Norsworthy; Melanie M Pearson
Journal:  Trends Microbiol       Date:  2016-12-22       Impact factor: 17.079

Review 3.  [The sodium-iodide symporter. Pathophysiologic, diagnostic and therapeutic significance].

Authors:  C Spitzweg
Journal:  Internist (Berl)       Date:  2003-04       Impact factor: 0.743

4.  A perchlorate sensitive iodide transporter in frogs.

Authors:  Deborah L Carr; James A Carr; Ray E Willis; Thomas A Pressley
Journal:  Gen Comp Endocrinol       Date:  2008-01-12       Impact factor: 2.822

5.  A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer.

Authors:  Vicki E Smith; Martin L Read; Andrew S Turnell; Rachel J Watkins; John C Watkinson; Greg D Lewy; Jim C W Fong; Sally R James; Margaret C Eggo; Kristien Boelaert; Jayne A Franklyn; Christopher J McCabe
Journal:  J Cell Sci       Date:  2009-08-25       Impact factor: 5.285

6.  Transcellular thiocyanate transport by human airway epithelia.

Authors:  Miryam A Fragoso; Vania Fernandez; Rosanna Forteza; Scott H Randell; Matthias Salathe; Gregory E Conner
Journal:  J Physiol       Date:  2004-09-02       Impact factor: 5.182

7.  Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy.

Authors:  Tanner S Miest; Marie Frenzke; Roberto Cattaneo
Journal:  Mol Ther       Date:  2013-08-05       Impact factor: 11.454

8.  Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.

Authors:  Anjali Mishra; Lily Pal; Saroj Kanta Mishra
Journal:  World J Surg       Date:  2007-09       Impact factor: 3.352

9.  Evidence for transcriptional and posttranscriptional alterations of the sodium/iodide symporter expression in hypofunctioning benign and malignant thyroid tumors.

Authors:  Séverine Trouttet-Masson; Samia Selmi-Ruby; Françoise Bernier-Valentin; Valérie Porra; Nicole Berger-Dutrieux; Myriam Decaussin; Jean-Louis Peix; Agnès Perrin; Claire Bournaud; Jacques Orgiazzi; Françoise Borson-Chazot; Brigitte Franc; Bernard Rousset
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

10.  Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.

Authors:  Miguel A Trujillo; Michael J Oneal; Julia Davydova; Elizabeth Bergert; Masato Yamamoto; John C Morris
Journal:  Breast Cancer Res       Date:  2009-07-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.